English

Sage Therapeutics, Inc.

EDGAR

SAGE Quarterly report (10-Q) · filed 2025-07-30

Annual consolidated revenue for 2024: about USD 41.24M, using the latest reported figures. The previous period, 2023, was about USD 86.46M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

31.7 million USD

2025 Q2 · USD

Exact inputs and evidence

Revenue: 31660000 USD Source

Operating margin

-170.46%

2025 Q2 · %

Exact inputs and evidence

Operating Income: -53969000 USD Source
Revenue: 31660000 USD Source

Operating cash flow

-58.7 million USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -140418000 USD Source
Operating Cash Flow: -81728000 USD Source

Cash and cash equivalents: 67.5 million USD 2025-06-30 Source
Exact value

67487000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 62.6 million shares 2025-06-30 Source
Exact value

62628219 shares

Reported share-count change

2.85% · 1.73 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

60894934 shares · 2024-06-30· Source
62628219 shares · 2025-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

70.4 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Revenue: 11871000 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 41243000 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 28427000 USD · 2024-01-01 – 2024-09-30 Source
Revenue: 14063000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 31660000 USD · 2025-04-01 – 2025-06-30 Source

Net income

-301 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Net income: -93551000 USD · 2024-07-01 – 2024-09-30 Source
Net income: -400666000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -304888000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -62214000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -49652000 USD · 2025-04-01 – 2025-06-30 Source

Operating cash flow

-289 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Operating cash flow: -200634000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -118269000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -267194000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -200634000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -81728000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -140418000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -81728000 USD · 2025-01-01 – 2025-03-31 Source

Capital expenditure

0 USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Capital expenditure: 0 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-07-30.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2024-12-31
Operating income: 11 of 11 periods available· newest 2024-12-31
Net income: 11 of 11 periods available· newest 2024-12-31
Operating cash flow: 11 of 11 periods available· newest 2024-12-31
Capital expenditure: 11 of 11 periods available· newest 2024-12-31
Total assets: 7 of 11 periods available· newest 2024-12-31
Total liabilities: 7 of 11 periods available· newest 2024-12-31
Current assets: 7 of 11 periods available· newest 2024-12-31
Current liabilities: 7 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-52.3%

Prior period

USD 86.46 million

2023-01-01 – 2023-12-31
Current period

USD 41.24 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

41243000 − 86455000 = -45212000 USD

86455000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
41243000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Year-over-year change in Revenue: -45212000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 41243000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#1749747 Filing: 000095017025017909 Input fundies:Revenue: 86455000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#1751419 Filing: 000095017025017909
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 140.82 million

Prior period

−USD 541.49 million

2023-01-01 – 2023-12-31
Current period

−USD 400.67 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-400666000 − -541489000 = 140823000 USD

-541489000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-400666000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Year-over-year change in Net income: 140823000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -400666000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#3663809 Filing: 000095017025017909 Input fundies:NetIncome: -541489000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#3665553 Filing: 000095017025017909
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 273.39 million

Prior period

−USD 540.59 million

2023-01-01 – 2023-12-31
Current period

−USD 267.19 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-267194000 − -540585000 = 273391000 USD

-540585000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-267194000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Year-over-year change in Operating cash flow: 273391000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -267194000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2255577 Filing: 000095017025017909 Input fundies:OperatingCashFlow: -540585000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2257444 Filing: 000095017025017909
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 553,000

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 553000 = -553000 USD

553000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Year-over-year change in Capital expenditure: -553000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2276200 Filing: 000095017025017909 Input fundies:CapitalExpenditure: 553000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2278044 Filing: 000095017025017909
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 41.24 million 100% of revenue
Operating costs Derived USD 473.61 million 1,148% of revenue
Operating income −USD 432.37 million −1,048% of revenue
Tax, interest and other Derived −USD 31.7 million −77% of revenue
Net income −USD 400.67 million −971% of revenue

Cash

Operating cash flow −USD 267.19 million −648% of revenue
Capital expenditure USD 0 0% of revenue
Free cash flow Derived −USD 267.19 million −648% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 536% of revenue.
2019 Operating loss: operating costs were 10,410% of revenue.
2020 Net income was higher than operating income, so the split is not drawn.
2021 Operating loss: operating costs were 7,407% of revenue.
2022 Operating loss: operating costs were 7,217% of revenue.
2023 Operating loss: operating costs were 771% of revenue.
2024 Operating loss: operating costs were 1,148% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	90273000	483511000 Derived	-393238000	-20356000 Derived	-372882000	-263531000 Derived	Source 2018-01-01 – 2018-12-31: 90273000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -393238000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -372882000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -260671000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2860000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	6868000	714992000 Derived	-708124000	-27886000 Derived	-680238000	-534457000 Derived	Source 2019-01-01 – 2019-12-31: 6868000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -708124000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -680238000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -528706000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 5751000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	1114200000	517974000 Derived	596226000	-9847000 Derived	606073000	663935000 Derived	Source 2020-01-01 – 2020-12-31: 1114200000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 596226000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 606073000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 664280000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 345000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	6308000	467217000 Derived	-460909000	-3017000 Derived	-457892000	-378554000 Derived	Source 2021-01-01 – 2021-12-31: 6308000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -460909000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -457892000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -378182000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 372000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	7686000	554675000 Derived	-546989000	-14205000 Derived	-532784000	-460973000 Derived	Source 2022-01-01 – 2022-12-31: 7686000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -546989000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -532784000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -460036000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 937000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	86455000	666304000 Derived	-579849000	-38360000 Derived	-541489000	-541138000 Derived	Source 2023-01-01 – 2023-12-31: 86455000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -579849000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -541489000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -540585000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 553000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	41243000	473613000 Derived	-432370000	-31704000 Derived	-400666000	-267194000 Derived	Source 2024-01-01 – 2024-12-31: 41243000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -432370000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -400666000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -267194000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 41.2M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	90273000	Revenue: 90273000 Open source
20192019-12-31	Revenue	6868000	Revenue: 6868000 Open source
20202020-12-31	Revenue	1114200000	Revenue: 1114200000 Open source
20212021-12-31	Revenue	6308000	Revenue: 6308000 Open source
20222022-12-31	Revenue	7686000	Revenue: 7686000 Open source
20232023-12-31	Revenue	86455000	Revenue: 86455000 Open source
20242024-12-31	Revenue	41243000	Revenue: 41243000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-52.3% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 90273000 Open source
20192019-12-31	Year over year	-92.4%	Revenue: 6868000 Open source Revenue: 90273000 Open source
20202020-12-31	Year over year	16,123.1%	Revenue: 1114200000 Open source Revenue: 6868000 Open source
20212021-12-31	Year over year	-99.4%	Revenue: 6308000 Open source Revenue: 1114200000 Open source
20222022-12-31	Year over year	21.8%	Revenue: 7686000 Open source Revenue: 6308000 Open source
20232023-12-31	Year over year	1,024.8%	Revenue: 86455000 Open source Revenue: 7686000 Open source
20242024-12-31	Year over year	-52.3%	Revenue: 41243000 Open source Revenue: 86455000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,048.3% 2024

Net margin -971.5% 2024

Free cash flow margin -647.9% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-435.6%	Operating Income: -393238000 Open source Revenue: 90273000 Open source
20192019-12-31	Operating margin	-10,310.5%	Operating Income: -708124000 Open source Revenue: 6868000 Open source
20202020-12-31	Operating margin	53.5%	Operating Income: 596226000 Open source Revenue: 1114200000 Open source
20212021-12-31	Operating margin	-7,306.7%	Operating Income: -460909000 Open source Revenue: 6308000 Open source
20222022-12-31	Operating margin	-7,116.7%	Operating Income: -546989000 Open source Revenue: 7686000 Open source
20232023-12-31	Operating margin	-670.7%	Operating Income: -579849000 Open source Revenue: 86455000 Open source
20242024-12-31	Operating margin	-1,048.3%	Operating Income: -432370000 Open source Revenue: 41243000 Open source
20182018-12-31	Net margin	-413.1%	Net Income: -372882000 Open source Revenue: 90273000 Open source
20192019-12-31	Net margin	-9,904.5%	Net Income: -680238000 Open source Revenue: 6868000 Open source
20202020-12-31	Net margin	54.4%	Net Income: 606073000 Open source Revenue: 1114200000 Open source
20212021-12-31	Net margin	-7,258.9%	Net Income: -457892000 Open source Revenue: 6308000 Open source
20222022-12-31	Net margin	-6,931.9%	Net Income: -532784000 Open source Revenue: 7686000 Open source
20232023-12-31	Net margin	-626.3%	Net Income: -541489000 Open source Revenue: 86455000 Open source
20242024-12-31	Net margin	-971.5%	Net Income: -400666000 Open source Revenue: 41243000 Open source
20182018-12-31	Free cash flow margin	-291.9%	Revenue: 90273000 Open source Operating Cash Flow: -260671000 Open source Capital Expenditure: 2860000 Open source
20192019-12-31	Free cash flow margin	-7,781.8%	Revenue: 6868000 Open source Operating Cash Flow: -528706000 Open source Capital Expenditure: 5751000 Open source
20202020-12-31	Free cash flow margin	59.6%	Revenue: 1114200000 Open source Operating Cash Flow: 664280000 Open source Capital Expenditure: 345000 Open source
20212021-12-31	Free cash flow margin	-6,001.2%	Revenue: 6308000 Open source Operating Cash Flow: -378182000 Open source Capital Expenditure: 372000 Open source
20222022-12-31	Free cash flow margin	-5,997.6%	Revenue: 7686000 Open source Operating Cash Flow: -460036000 Open source Capital Expenditure: 937000 Open source
20232023-12-31	Free cash flow margin	-625.9%	Revenue: 86455000 Open source Operating Cash Flow: -540585000 Open source Capital Expenditure: 553000 Open source
20242024-12-31	Free cash flow margin	-647.9%	Revenue: 41243000 Open source Operating Cash Flow: -267194000 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -267.2M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-260671000	Operating Cash Flow: -260671000 Open source
20192019-12-31	Operating cash flow	-528706000	Operating Cash Flow: -528706000 Open source
20202020-12-31	Operating cash flow	664280000	Operating Cash Flow: 664280000 Open source
20212021-12-31	Operating cash flow	-378182000	Operating Cash Flow: -378182000 Open source
20222022-12-31	Operating cash flow	-460036000	Operating Cash Flow: -460036000 Open source
20232023-12-31	Operating cash flow	-540585000	Operating Cash Flow: -540585000 Open source
20242024-12-31	Operating cash flow	-267194000	Operating Cash Flow: -267194000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -267.2M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-263531000	Operating Cash Flow: -260671000 Open source Capital Expenditure: 2860000 Open source
20192019-12-31	Free cash flow	-534457000	Operating Cash Flow: -528706000 Open source Capital Expenditure: 5751000 Open source
20202020-12-31	Free cash flow	663935000	Operating Cash Flow: 664280000 Open source Capital Expenditure: 345000 Open source
20212021-12-31	Free cash flow	-378554000	Operating Cash Flow: -378182000 Open source Capital Expenditure: 372000 Open source
20222022-12-31	Free cash flow	-460973000	Operating Cash Flow: -460036000 Open source Capital Expenditure: 937000 Open source
20232023-12-31	Free cash flow	-541138000	Operating Cash Flow: -540585000 Open source Capital Expenditure: 553000 Open source
20242024-12-31	Free cash flow	-267194000	Operating Cash Flow: -267194000 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

15% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	9.4%	Total Liabilities: 89734000 Open source Total Assets: 952705000 Open source
20192019-12-31	Liabilities / assets	12.9%	Total Liabilities: 139495000 Open source Total Assets: 1084150000 Open source
20202020-12-31	Liabilities / assets	4%	Total Liabilities: 86912000 Open source Total Assets: 2159246000 Open source
20212021-12-31	Liabilities / assets	5.3%	Total Liabilities: 96257000 Open source Total Assets: 1825288000 Open source
20222022-12-31	Liabilities / assets	7.7%	Total Liabilities: 103850000 Open source Total Assets: 1356449000 Open source
20232023-12-31	Liabilities / assets	9.4%	Total Liabilities: 82747000 Open source Total Assets: 882277000 Open source
20242024-12-31	Liabilities / assets	15%	Total Liabilities: 82133000 Open source Total Assets: 547222000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.42× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	10.98×	Current Assets: 944695000 Open source Current Liabilities: 86030000 Open source
20192019-12-31	Current assets / current liabilities	9.23×	Current Assets: 1035093000 Open source Current Liabilities: 112128000 Open source
20202020-12-31	Current assets / current liabilities	31.58×	Current Assets: 2122370000 Open source Current Liabilities: 67204000 Open source
20212021-12-31	Current assets / current liabilities	21.14×	Current Assets: 1800643000 Open source Current Liabilities: 85193000 Open source
20222022-12-31	Current assets / current liabilities	13.47×	Current Assets: 1336980000 Open source Current Liabilities: 99259000 Open source
20232023-12-31	Current assets / current liabilities	10.51×	Current Assets: 869350000 Open source Current Liabilities: 82747000 Open source
20242024-12-31	Current assets / current liabilities	7.42×	Current Assets: 531301000 Open source Current Liabilities: 71615000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 94.5 million Exact value Exact value: -94495000 USD 2015-01-01 – 2015-12-31: -94495000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2015-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -94495000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -94495000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459018002772/sage-20171231.xml#124611 Filing: 000156459018002772 The citation records this snapshot. The page link may show a newer release later.	−USD 70.68 million Exact value Exact value: -70681000 USD 2015-01-01 – 2015-12-31: -70681000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2015-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -70681000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70681000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459018002772/sage-20171231.xml#152886 Filing: 000156459018002772 The citation records this snapshot. The page link may show a newer release later.	USD 198,000 Exact value Exact value: 198000 USD 2015-01-01 – 2015-12-31: 198000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2015-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 198000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 198000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459018002772/sage-20171231.xml#154477 Filing: 000156459018002772 The citation records this snapshot. The page link may show a newer release later.	−USD 70.88 million Calculation and evidence -70681000 − 198000 USD Exact free cash flow: -70879000 USD 2015-01-01 – 2015-12-31: -70681000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 198000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2015-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -70879000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70681000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459018002772/sage-20171231.xml#152886 Filing: 000156459018002772 Input fundies:CapitalExpenditure: 198000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459018002772/sage-20171231.xml#154477 Filing: 000156459018002772 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 158.99 million Exact value Exact value: -158987000 USD 2016-01-01 – 2016-12-31: -158987000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2016-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -158987000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -158987000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459019003191/sage-20181231.xml#148257 Filing: 000156459019003191 The citation records this snapshot. The page link may show a newer release later.	−USD 118.68 million Exact value Exact value: -118678000 USD 2016-01-01 – 2016-12-31: -118678000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2016-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -118678000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -118678000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459019003191/sage-20181231.xml#178835 Filing: 000156459019003191 The citation records this snapshot. The page link may show a newer release later.	USD 1.42 million Exact value Exact value: 1421000 USD 2016-01-01 – 2016-12-31: 1421000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2016-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 1421000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1421000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459019003191/sage-20181231.xml#180848 Filing: 000156459019003191 The citation records this snapshot. The page link may show a newer release later.	−USD 120.1 million Calculation and evidence -118678000 − 1421000 USD Exact free cash flow: -120099000 USD 2016-01-01 – 2016-12-31: -118678000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1421000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2016-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -120099000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -118678000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459019003191/sage-20181231.xml#178835 Filing: 000156459019003191 Input fundies:CapitalExpenditure: 1421000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459019003191/sage-20181231.xml#180848 Filing: 000156459019003191 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 270.12 million Exact value Exact value: -270120000 USD 2017-01-01 – 2017-12-31: -270120000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2017-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -270120000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -270120000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459020007021/sage-10k_20191231.htm#3534742 Filing: 000156459020007021 The citation records this snapshot. The page link may show a newer release later.	−USD 219.28 million Exact value Exact value: -219277000 USD 2017-01-01 – 2017-12-31: -219277000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2017-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -219277000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -219277000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459020007021/sage-10k_20191231.htm#2509485 Filing: 000156459020007021 The citation records this snapshot. The page link may show a newer release later.	USD 1.36 million Exact value Exact value: 1360000 USD 2017-01-01 – 2017-12-31: 1360000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2017-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 1360000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1360000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459020007021/sage-10k_20191231.htm#2532565 Filing: 000156459020007021 The citation records this snapshot. The page link may show a newer release later.	−USD 220.64 million Calculation and evidence -219277000 − 1360000 USD Exact free cash flow: -220637000 USD 2017-01-01 – 2017-12-31: -219277000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1360000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2017-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -220637000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -219277000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459020007021/sage-10k_20191231.htm#2509485 Filing: 000156459020007021 Input fundies:CapitalExpenditure: 1360000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459020007021/sage-10k_20191231.htm#2532565 Filing: 000156459020007021 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 372.88 million Exact value Exact value: -372882000 USD 2018-01-01 – 2018-12-31: -372882000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2018-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -372882000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -372882000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459021007819/sage-10k_20201231.htm#3484150 Filing: 000156459021007819 The citation records this snapshot. The page link may show a newer release later.	−USD 260.67 million Exact value Exact value: -260671000 USD 2018-01-01 – 2018-12-31: -260671000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2018-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -260671000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -260671000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459021007819/sage-10k_20201231.htm#2378807 Filing: 000156459021007819 The citation records this snapshot. The page link may show a newer release later.	USD 2.86 million Exact value Exact value: 2860000 USD 2018-01-01 – 2018-12-31: 2860000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2018-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 2860000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2860000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459021007819/sage-10k_20201231.htm#2401858 Filing: 000156459021007819 The citation records this snapshot. The page link may show a newer release later.	−USD 263.53 million Calculation and evidence -260671000 − 2860000 USD Exact free cash flow: -263531000 USD 2018-01-01 – 2018-12-31: -260671000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2860000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2018-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -263531000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -260671000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459021007819/sage-10k_20201231.htm#2378807 Filing: 000156459021007819 Input fundies:CapitalExpenditure: 2860000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459021007819/sage-10k_20201231.htm#2401858 Filing: 000156459021007819 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 680.24 million Exact value Exact value: -680238000 USD 2019-01-01 – 2019-12-31: -680238000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2019-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -680238000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -680238000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459022006495/sage-10k_20211231.htm#3605802 Filing: 000156459022006495 The citation records this snapshot. The page link may show a newer release later.	−USD 528.71 million Exact value Exact value: -528706000 USD 2019-01-01 – 2019-12-31: -528706000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2019-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -528706000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -528706000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459022006495/sage-10k_20211231.htm#2431571 Filing: 000156459022006495 The citation records this snapshot. The page link may show a newer release later.	USD 5.75 million Exact value Exact value: 5751000 USD 2019-01-01 – 2019-12-31: 5751000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2019-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 5751000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5751000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459022006495/sage-10k_20211231.htm#2454593 Filing: 000156459022006495 The citation records this snapshot. The page link may show a newer release later.	−USD 534.46 million Calculation and evidence -528706000 − 5751000 USD Exact free cash flow: -534457000 USD 2019-01-01 – 2019-12-31: -528706000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 5751000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2019-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -534457000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -528706000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459022006495/sage-10k_20211231.htm#2431571 Filing: 000156459022006495 Input fundies:CapitalExpenditure: 5751000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000156459022006495/sage-10k_20211231.htm#2454593 Filing: 000156459022006495 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 606.07 million Exact value Exact value: 606073000 USD 2020-01-01 – 2020-12-31: 606073000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2020-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: 606073000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 606073000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017023002964/sage-20221231.htm#4107473 Filing: 000095017023002964 The citation records this snapshot. The page link may show a newer release later.	USD 664.28 million Exact value Exact value: 664280000 USD 2020-01-01 – 2020-12-31: 664280000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2020-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: 664280000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 664280000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017023002964/sage-20221231.htm#2484893 Filing: 000095017023002964 The citation records this snapshot. The page link may show a newer release later.	USD 345,000 Exact value Exact value: 345000 USD 2020-01-01 – 2020-12-31: 345000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2020-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 345000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 345000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017023002964/sage-20221231.htm#2510113 Filing: 000095017023002964 The citation records this snapshot. The page link may show a newer release later.	USD 663.94 million Calculation and evidence 664280000 − 345000 USD Exact free cash flow: 663935000 USD 2020-01-01 – 2020-12-31: 664280000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 345000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2020-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: 663935000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 664280000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017023002964/sage-20221231.htm#2484893 Filing: 000095017023002964 Input fundies:CapitalExpenditure: 345000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017023002964/sage-20221231.htm#2510113 Filing: 000095017023002964 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 457.89 million Exact value Exact value: -457892000 USD 2021-01-01 – 2021-12-31: -457892000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2021-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -457892000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -457892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017024014934/sage-20231231.htm#3043754 Filing: 000095017024014934 The citation records this snapshot. The page link may show a newer release later.	−USD 378.18 million Exact value Exact value: -378182000 USD 2021-01-01 – 2021-12-31: -378182000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2021-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -378182000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -378182000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017024014934/sage-20231231.htm#1932076 Filing: 000095017024014934 The citation records this snapshot. The page link may show a newer release later.	USD 372,000 Exact value Exact value: 372000 USD 2021-01-01 – 2021-12-31: 372000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2021-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 372000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 372000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017024014934/sage-20231231.htm#1947791 Filing: 000095017024014934 The citation records this snapshot. The page link may show a newer release later.	−USD 378.55 million Calculation and evidence -378182000 − 372000 USD Exact free cash flow: -378554000 USD 2021-01-01 – 2021-12-31: -378182000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 372000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2021-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -378554000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -378182000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017024014934/sage-20231231.htm#1932076 Filing: 000095017024014934 Input fundies:CapitalExpenditure: 372000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017024014934/sage-20231231.htm#1947791 Filing: 000095017024014934 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 532.78 million Exact value Exact value: -532784000 USD 2022-01-01 – 2022-12-31: -532784000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2022-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -532784000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -532784000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#3667316 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	−USD 460.04 million Exact value Exact value: -460036000 USD 2022-01-01 – 2022-12-31: -460036000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2022-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -460036000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -460036000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2259292 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	USD 937,000 Exact value Exact value: 937000 USD 2022-01-01 – 2022-12-31: 937000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2022-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 937000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 937000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2279879 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	−USD 460.97 million Calculation and evidence -460036000 − 937000 USD Exact free cash flow: -460973000 USD 2022-01-01 – 2022-12-31: -460036000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 937000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2022-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -460973000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -460036000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2259292 Filing: 000095017025017909 Input fundies:CapitalExpenditure: 937000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2279879 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 541.49 million Exact value Exact value: -541489000 USD 2023-01-01 – 2023-12-31: -541489000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2023-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -541489000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -541489000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#3665553 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	−USD 540.59 million Exact value Exact value: -540585000 USD 2023-01-01 – 2023-12-31: -540585000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2023-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -540585000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -540585000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2257444 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	USD 553,000 Exact value Exact value: 553000 USD 2023-01-01 – 2023-12-31: 553000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2023-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 553000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 553000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2278044 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	−USD 541.14 million Calculation and evidence -540585000 − 553000 USD Exact free cash flow: -541138000 USD 2023-01-01 – 2023-12-31: -540585000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 553000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2023-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -541138000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -540585000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2257444 Filing: 000095017025017909 Input fundies:CapitalExpenditure: 553000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2278044 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 400.67 million Exact value Exact value: -400666000 USD 2024-01-01 – 2024-12-31: -400666000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Net Income: -400666000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -400666000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#3663809 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	−USD 267.19 million Exact value Exact value: -267194000 USD 2024-01-01 – 2024-12-31: -267194000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Operating Cash Flow: -267194000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -267194000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2255577 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2276200 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.	−USD 267.19 million Calculation and evidence -267194000 − 0 USD Exact free cash flow: -267194000 USD 2024-01-01 – 2024-12-31: -267194000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sage Therapeutics, Inc. · 2024-12-31 Sage Therapeutics, Inc. (edgar:1597553) Free cash flow: -267194000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:55:02Z Snapshot: 2c7186448b82268bbc626f1fdc824bb1d5db8cef4222794f75ffa82dae119a5f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1597553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -267194000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2255577 Filing: 000095017025017909 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1597553/000095017025017909/sage-20241231.htm#2276200 Filing: 000095017025017909 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

70 filings · 2,752 latest values · 2,752 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001597553, 1597553, SAGE, edgar:1597553

Also known as Sage Therapeutics, Inc.

Sage Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation